(Z)-3-(4-nitrophenyl)propenal

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醛
• 英文名称: (Z)-3-(4-nitrophenyl)propenal
• 英文别名: (Z)-4-nitrocinnamaldehyde；(Z)-3-(4-nitrophenyl)prop-2-enal
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: ALGQVMMYDWQDEC-UPHRSURJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-3-(4-nitrophenyl)propenal 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Design and structure optimization of novel butenolide derivatives as low bee-toxicity candidates

  摘要：

  DOI：

  10.1016/j.molstruc.2023.135257

文献信息

• A novel hydrazide type organocatalyst for enantioselective Diels–Alder reactions
  作者：Ichiro Suzuki、Masafumi Ando、Rumiko Shimabara、Ai Hirata、Kei Takeda

  DOI：10.1039/c0ob01138j

  日期：——

  The development of a new class of hydrazide type organocatalyst, (4R,5R)-1,3-bis(isopropylamino)-4,5-dihenylimidazolidin-2-one 2a, for enantioselective Diels–Alder reactions between cyclopentadiene and α,β-unsaturated aldehydes are presented. The new organocatalyst 2a promoted the reaction, affording Diels–Alder adducts in good yields with good levels of enantioselectivity.

  本文介绍了一类新型肼型有机催化剂（4R,5R）-1,3-双（异丙氨基）-4,5-二苯基咪唑啉-2-酮2a在环戊二烯与α,β-不饱和醛的对映选择性狄尔斯-阿尔德反应中的发展。新型有机催化剂2a促进了反应的进行，以良好的产率和较高水平的手性选择性得到了狄尔斯-阿尔德加成产物。
• Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
  申请人：——

  公开号：US20020052408A1

  公开（公告）日：2002-05-02

  Novel sulfate ester agents and the use of those agents for treating gastroesophageal reflux disease (GERD) are described, exemplary agents being of the formula: 1 wherein X is —OCH 2 — or —CH 2 O—; Y is a group pendant from X comprising at least one —OSO 3 R 4 moiety, wherein R 4 is H or a pharmaceutically acceptable cation; n is an integer from 1-3; and R 1 and R 2 are each independently selected from the group consisting of —H, a halogen with an atomic number from 9 to 53, —SO 3 R 4 , —NCS, —NCO, —NH(CO)—OR 3 , —NH(CS)SR 3 , —NH(C═NH)OR 3 , —NHCOCH 2 Cl, —NHCOCH 2 Br, —NHCO—CH═CH 2 , —NHC(O)—CF 3 , wherein R 4 is H or a pharmaceutically acceptable cation.

  描述了新型硫酸酯类药剂以及利用这些药剂治疗胃食管反流病（GERD）的方法，示例药剂的结构如下：其中X为—O —或—CH2O—；Y是从X中悬挂的一个含有至少一个—OSO3R4基团的基团，其中R4为H或药用可接受的阳离子；n为1-3的整数；R1和R2各自独立地选择自—H、原子序数为9至53的卤素、—SO3R4、—NCS、—NCO、—NH(CO)—OR3、—NH(CS)SR3、—NH(C═NH)OR3、—NHCO Cl、—NHCO Br、—NHCO—CH═CH2、—NHC(O)—CF3的基团，其中R4为H或药用可接受的阳离子。
• Cyclization reactions of coumarin derivatives: Chemo- and regioselectivity effects of oxygen/sulfur isosteric replacement
  作者：Giovanni Palmisano、Lucio Toma、Rita Annunziata、Silvia Tagliapietra、Alessandro Barge、Giancarlo Cravotto

  DOI：10.1002/jhet.5570440221

  日期：2007.3

  We synthesized several sulfur isosters of ferulenol and related prenylcoumarins from Ferula communis preliminary to finding whether the antitubercular activity of these natural compounds might be dissociated from their antithrombin activity. Direct thionation of ferprenine, an instance of “diversity-oriented” synthesis, yielded a mixture of three thiocoumarin derivatives. When 4-hydroxy-2-deoxy-2-thiocoumarin

  我们从Ferula communis合成了几种阿魏烯醇和相关异戊二烯香豆素的硫等排体初步发现这些天然化合物的抗结核活性是否可能与其抗凝血酶活性分离。所谓的“以多样性为导向”合成的实例是直接对硫丁胺进行硫磺化，生成了三种硫代香豆素衍生物的混合物。当4-羟基-2-脱氧-2-硫代香豆素与法呢醛和其他α，β-不饱和醛反应时，位置2的等位氧-硫取代令人惊讶地引起串联Knoevenagel-电环反应中的区域化学转化，普遍提供线性加合物。广泛调查了各种替代的食用油，突显出Knoevenagel和Michael加成之间的竞争。通过考虑空间和电子因素以及与催化剂形成复合物的能量计算，使该结果合理化。
• US6743820B2
  申请人：——

  公开号：US6743820B2

  公开（公告）日：2004-06-01
• [EN] METHODS FOR PROTECTION OF STRATIFIED SQUAMOUS EPITHELIUM AGAINST INJURY BY NOXIOUS SUBSTANCES AND NOVEL AGENTS FOR USE THEREFOR<br/>[FR] PROCEDES SERVANT A PROTEGER UN EPITHELIUM PAVIMENTEUX CONTRE DES LESIONS OCCASIONNEES PAR DES SUBSTANCES NOCIVES ET NOUVEAUX AGENTS CORRESPONDANTS
  申请人：UNIV TULANE

  公开号：WO2002004411A1

  公开（公告）日：2002-01-17

  Novel sulfate ester agents and the use of those agents for treating gastroesophageal reflux disease (GERD) are described, exemplary agents being of formula (I), wherein X is OCH2- or CH2O-; Y is a group pendant from X comprising at least one -OSO3R4 moiety, wherein R4 is H or a pharmaceutically acceptable cation; n is an integer from 1-3; and R?1 and R2¿ are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, -SO¿3R?4,-NCS,-NCO, -NH(CO)-OR3,-NH(CS)SR3, -NH(C=NH)OR3,-NHCOCH¿2?CL,-NHCOCH2BR, -NHCO-CH=CH2 ,-NHC(O)-CF3, wherein R?4¿ is H or a pharmaceutically acceptable cation.